Inventor · disambiguated record
Michael Lainchbury
Also filed as: LAINCHBURY MICHAEL
16 granted patents·3 pending applications·49 citations·filing 2012–2024
91Inventor score
Top patents by PatentIndex Score
19 records- 0195US11566003B2Isoquinolines as inhibitors of HPK1GENENTECH INC·Filed 2020·Granted Jan 31, 2023·4 cites·31 claims
- 0292US9765059B25-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic useCANCER RES TECH LTD·Filed 2016·Granted Sep 19, 2017·6 cites·20 claims
- 0391US9403797B25-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic useCANCER RES TECH LTD·Filed 2015·Granted Aug 2, 2016·6 cites·38 claims
- 0490US10407424B2Naphthyridines as inhibitors of HPK1GENENTECH INC·Filed 2018·Granted Sep 10, 2019·5 cites·72 claims
- 0586US9890152B2Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutantsGENENTECH INC·Filed 2015·Granted Feb 13, 2018·7 cites·29 claims
- 0684US9951064B2Azaindazole compounds as inhibitors of T790M containing EGFR mutantsGENENTECH INC·Filed 2016·Granted Apr 24, 2018·5 cites·15 claims
- 0783US11787792B25-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereofCANCER RESEARCH TECH LTD·Filed 2020·Granted Oct 17, 2023·1 cites·21 claims
- 0881US11034692B1Naphthyridines as inhibitors of HPK1GENENTECH INC·Filed 2019·Granted Jun 15, 2021·1 cites·20 claims
- 0981US9663503B25-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereofCANCER RES TECH LTD·Filed 2013·Granted May 30, 2017·5 cites·19 claims
- 1078US10259806B25-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereofCANCER RESEARCH TECH LTD·Filed 2017·Granted Apr 16, 2019·2 cites·16 claims
- 1175US9040540B25-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic useCANCER REC TECH LTD·Filed 2012·Granted May 26, 2015·7 cites·39 claims
- 1275US2024368170A1Cinnoline compounds and uses thereofGENENTECH INC·Filed 2024·Application pending·0 cites
- 1367US10952995B2Azaindoles as inhibitors of HPK1GENENTECH INC·Filed 2019·Granted Mar 23, 2021·0 cites·32 claims
- 1464US11944606B2Azaindoles as inhibitors of HPK1GENENTECH INC·Filed 2021·Granted Apr 2, 2024·0 cites·20 claims
- 1562US2022073520A1Cinnoline compounds and uses thereofGENENTECH INC·Filed 2021·Application pending·0 cites
- 1654US12208088B2Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereofGENENTECH INC·Filed 2021·Granted Jan 28, 2025·0 cites·29 claims
- 1754US2018282282A1Isoquinolines as inhibitors of hpk1GENENTECH INC·Filed 2018·Application pending·0 cites
- 1853US12378249B2Isoquinoline compounds and uses thereofGENENTECH INC·Filed 2021·Granted Aug 5, 2025·0 cites·25 claims
- 1953US12297210B2Naphthyridine compounds and uses thereofGENENTECH INC·Filed 2021·Granted May 13, 2025·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Michael Lainchbury files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →